TGFB1 and cancer: Overall, these results suggest that Rb9 can modulate human monocyte-derived dendritic cells activity, especially in cancer patient cells, stimulating tolerogenic cells (biased either in vitro, by TGF-β with IL-10, or in vivo by the presence of cancer) and containing the activation of hyperstimulated cells (by LPS, for example).